|
|
Blood, 15 February 2008, Vol. 111, No. 4, pp. 2152-2154.
Prepublished online as a Blood First Edition Paper on November 28, 2007; DOI 10.1182/blood-2007-10-116111.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Brief Report
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Stefan Lob1,2,
Alfred Konigsrainer1,
Richard Schafer3,
Hans-Georg Rammensee2,
Gerhard Opelz4, and
Peter Terness4
1 Department of General, Visceral and Transplant Surgery, University Hospital of Tubingen, Tubingen;
2 Institute for Cell Biology, Department of Immunology, Eberhard Karls University of Tubingen, Tubingen;
3 Institute of Clinical and Experimental Transfusion Medicine, Eberhard Karls University of Tubingen, Tubingen; and
4 Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
Clinical trials have been started with the aim of inducing tumor immunity by blocking the immunosuppressive action of indoleamine-2,3-dioxygenase (IDO) with the IDO2-inhibitor dextro-1-methyl-tryptophan (D-1MT). Here we show that human dendritic cells (DCs) express both IDO-1 and IDO-2, but that only IDO1 mediates tryptophan catabolism; furthermore, its activity is blocked by levo-1MT, whereas D-1MT is inefficient. Consequently, in humans any possible antitumor effects of D-1MT cannot be attributed to abrogation of IDO activity in DCs as described in this study.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Qian, J. Villella, P. K. Wallace, P. Mhawech-Fauceglia, J. D. Tario Jr., C. Andrews, J. Matsuzaki, D. Valmori, M. Ayyoub, P. J. Frederick, et al.
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Cancer Res.,
July 1, 2009;
69(13):
5498 - 5504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Opitz, U. M. Litzenburger, C. Lutz, T. V. Lanz, I. Tritschler, A. Koppel, E. Tolosa, M. Hoberg, J. Anderl, W. K. Aicher, et al.
Toll-Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow-Derived Mesenchymal Stem Cells by Inducing Indoleamine-2,3-dioxygenase-1 via Interferon-{beta} and Protein Kinase R
Stem Cells,
April 1, 2009;
27(4):
909 - 919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Maby-El Hajjami, P. Ame-Thomas, C. Pangault, O. Tribut, J. DeVos, R. Jean, N. Bescher, C. Monvoisin, J. Dulong, T. Lamy, et al.
Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase
Cancer Res.,
April 1, 2009;
69(7):
3228 - 3237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood,
March 12, 2009;
113(11):
2394 - 2401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. O'Connor, M. A. Lawson, C. Andre, E. M. Briley, S. S. Szegedi, J. Lestage, N. Castanon, M. Herkenham, R. Dantzer, and K. W. Kelley
Induction of IDO by Bacille Calmette-Guerin Is Responsible for Development of Murine Depressive-Like Behavior
J. Immunol.,
March 1, 2009;
182(5):
3202 - 3212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-C. Yen, C.-C. Lin, Y.-L. Chen, S.-S. Huang, H.-J. Yang, C.-P. Chang, H.-Y. Lei, and M.-D. Lai
A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
Clin. Cancer Res.,
January 15, 2009;
15(2):
641 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
